Published in Ann Oncol on April 01, 1997
Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies. J Cancer Res Clin Oncol (2013) 1.08
Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patients. Br J Cancer (2006) 0.88
Mechanisms of resistance to alkylating agents. Cytotechnology (1998) 0.84
Significance of serum butyrylcholinesterase levels in oral cancer. Australas Med J (2011) 0.79
Drug resistance markers: are they bad or good? Ann Oncol (1997) 0.75
Roots of clinical resistance to STI-571 cancer therapy. Science (2001) 9.78
Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet (1997) 6.53
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst (2000) 5.62
Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer (1995) 5.24
Epidermal growth factor receptor in human breast cancer: correlation with steroid hormone receptors and axillary lymph node involvement. Eur J Cancer Clin Oncol (1988) 3.92
Effect of a nicotine-free inhalator as part of a smoking-cessation programme. Eur Respir J (2011) 3.25
Class II versus class III radical hysterectomy in stage IB-IIA cervical cancer: a prospective randomized study. Gynecol Oncol (2001) 2.34
Clinical effects of a standardized soy extract in postmenopausal women: a pilot study. Menopause (2000) 2.27
Long-term analysis of clinical outcome and complications in locally advanced cervical cancer patients administered concomitant chemoradiation followed by radical surgery. Gynecol Oncol (2010) 2.27
Modulation of basal and squamous cell carcinoma by endogenous estrogen in mouse models of skin cancer. Carcinogenesis (2008) 2.19
Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst (2000) 2.06
Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer (2001) 2.02
Pattern of cancer risk in persons with AIDS in Italy in the HAART era. Br J Cancer (2009) 1.95
Human immunodeficiency virus seroprevalence and condom use among female sex workers in Italy. Sex Transm Dis (1998) 1.87
Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol (2002) 1.82
In vitro evaluation of newly developed chalcone analogues in human cancer cells. Cancer Chemother Pharmacol (2000) 1.77
Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer (2007) 1.72
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer (2003) 1.70
Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer (1996) 1.66
Oestrogens and obesity as risk factors for endometrial cancer in Italy. Int J Epidemiol (1982) 1.64
Apoptosis. Biochemical events and relevance to cancer chemotherapy. FEBS Lett (1992) 1.62
Sonographic features of decidualized ovarian endometriosis suspicious for malignancy. Ultrasound Obstet Gynecol (2004) 1.62
L-Asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase. Ann Oncol (1996) 1.52
Lymphatic spread of cervical cancer: an anatomical and pathological study based on 225 radical hysterectomies with systematic pelvic and aortic lymphadenectomy. Gynecol Oncol (1996) 1.49
Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol (2001) 1.48
Corticotropin-releasing hormone induces an exaggerated response of adrenocorticotropic hormone and cortisol in polycystic ovary syndrome. Fertil Steril (1995) 1.47
Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer (2006) 1.46
Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer (1995) 1.44
Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). Ann Oncol (2007) 1.44
Progression of conservatively treated endometrial carcinoma after full term pregnancy: a case report. Gynecol Oncol (2005) 1.43
Treatment with a gonadotrophin releasing hormone agonist before hysterectomy for leiomyomas: results of a multicentre, randomised controlled trial. Br J Obstet Gynaecol (1998) 1.43
Natural killer activity of lymphoid cells isolated from human ascitic ovarian tumors. Int J Cancer (1980) 1.43
Generation of multinuclear tartrate-resistant acid phosphatase positive osteoclasts in liquid culture of purified human peripheral blood CD34+ progenitors. Br J Haematol (1997) 1.42
Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin. Ann Oncol (1999) 1.42
Cisplatin and vinorelbine as neoadjuvant chemotherapy in locally advanced cervical cancer: a phase II study. Int J Gynecol Cancer (2003) 1.41
Animal foods, protein, calcium and prostate cancer risk: the European Prospective Investigation into Cancer and Nutrition. Br J Cancer (2008) 1.38
Complete response to pre-operative chemotherapy in stage III B cervical carcinoma. Case report. Br J Obstet Gynaecol (1988) 1.37
Longitudinal evaluation of uterine myoma growth during pregnancy. A sonographic study. J Ultrasound Med (1992) 1.37
Measurement of the sequence specificity of covalent DNA modification by antineoplastic agents using Taq DNA polymerase. Nucleic Acids Res (1991) 1.34
Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci U S A (2000) 1.34
Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: a meta-analysis. Br J Cancer (1997) 1.33
Spatiotemporal dynamics of the electrical network activity in the root apex. Proc Natl Acad Sci U S A (2009) 1.32
Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer (2001) 1.31
Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol (2009) 1.31
Significance of epidermal growth factor receptor in advanced ovarian cancer. J Clin Oncol (1992) 1.31
p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res (1997) 1.31
Selective DNA interaction of the novel distamycin derivative FCE 24517. Cancer Res (1991) 1.31
Distamycins inhibit the binding of OTF-1 and NFE-1 transfactors to their conserved DNA elements. Nucleic Acids Res (1989) 1.28
Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents. Int J Cancer (1996) 1.27
GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer (2001) 1.27
Pure ovarian immature teratoma, a unique and curable disease: 10 years' experience of 32 prospectively treated patients. Obstet Gynecol (1994) 1.26
In vitro and in vivo methazolastone-induced DNA damage and repair in L-1210 leukemia sensitive and resistant to chloroethylnitrosoureas. Cancer Res (1987) 1.26
Distribution of paclitaxel within the nervous system of the rat after repeated intravenous administration. Neurotoxicology (2000) 1.25
Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series. Ann Oncol (2012) 1.23
L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure. Ann Oncol (2000) 1.23
A randomized study comparing retroperitoneal drainage with no drainage after lymphadenectomy in gynecologic malignancies. Gynecol Oncol (1997) 1.23
Survival and reproductive function after treatment of malignant germ cell ovarian tumors. J Clin Oncol (2001) 1.21
p21WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth. Cancer Res (1997) 1.21
Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin Cancer Res (1998) 1.21
Conservative surgery for stage I ovarian carcinoma in women of childbearing age. Br J Obstet Gynaecol (1997) 1.21
Cell cycle checkpoint efficiency and cellular response to paclitaxel in prostate cancer cells. Prostate (2001) 1.18
Analysis of cyclin E and CDK2 in ovarian cancer: gene amplification and RNA overexpression. Int J Cancer (1998) 1.18
Treatment of acute respiratory failure with low-frequency positive-pressure ventilation and extracorporeal removal of CO2. Lancet (1980) 1.17
Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters. Br J Cancer (2005) 1.17
The EpiLink record linkage software: presentation and results of linkage test on cancer registry files. Methods Inf Med (2005) 1.16
Is chloromethyl-X-rosamine useful in measuring mitochondrial transmembrane potential? Cytometry (1998) 1.15
Surgery by minilaparotomy in benign gynecologic disease. Obstet Gynecol (1996) 1.15
Brain metastases from endometrial carcinoma. Gynecol Oncol (1996) 1.15
Preoperative concomitant chemoradiotherapy in locally advanced cervical cancer: safety, outcome, and prognostic measures. Gynecol Oncol (2007) 1.15
p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol (2000) 1.14